Intra-Cellular Therapies Inc. (ITCI)
NASDAQ (NGS) Summary
ITCI Chart
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwinds Strategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026 Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J.
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular shareholders. Halper Sadeh encourages Intra-Cellular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation.
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Intra-Cellular Therapies Inc. (ITCI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Intra-Cellular Therapies Inc. ever had a stock split?
Intra-Cellular Therapies Inc. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Dr. Sharon Mates Ph.D. CEO | NASDAQ (NGS) Exchange | US46116X1019 ISIN |
| US Country | 610 Employees | - Last Dividend | - Last Split | 7 Jan 2014 IPO Date |
Overview
Intra-Cellular Therapies, Inc. is a forward-looking biopharmaceutical company engaged in the innovative realm of developing small molecule drugs aimed at fulfilling the unmet medical needs within neuropsychiatric and neurological disorders. By focusing on the intricate mechanisms of intracellular signaling within the central nervous system (CNS), the company pioneers in addressing some of the most challenging conditions affecting mental health today. Founded in 2002 and based in New York, New York, Intra-Cellular Therapies is at the forefront of bringing novel treatments from the laboratory to the clinic, with an emphasis on the U.S. market.
Products and Services
- CAPLYTA (Lumateperone) - Currently offered for the treatment of schizophrenia and bipolar depression in adults, CAPLYTA represents Intra-Cellular Therapies’ commitment to addressing severe mental illnesses with a need for better treatment options.
- Lumateperone - Beyond its approved uses, Lumateperone is in a Phase 3 clinical trial stage aiming to expand its application to treat various depressive disorders. This exploration highlights the company’s continuous efforts to broaden the therapeutic utility of its lead compound.
- Lenrispodun (ITI-214) - In development for the treatment of Parkinson's disease, CNS conditions, and other disorders, Lenrispodun exemplifies the company’s venture into addressing neurological disorders with significant unmet needs.
- ITI-1284 - Targeted for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia, ITI-1284 reflects Intra-Cellular Therapies’ dedication to combating the challenges faced by aging populations.
- ITI-333 - This compound is under development for an array of conditions, including substance use disorders, pain, and psychiatric comorbidities such as depression, anxiety, and sleep disorders. ITI-333 embodies the company’s holistic approach to tackling complex, intertwined health issues.
Contact Information
